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C erebral cavernousmalformations (CCMs; cavernousangio-mas, cavernomas) are low-flow, hemorrhagic vascular le-sions of the central nervous system that affect 0.16% to
0.5% of the population.1 Anatomically, they are composed of ab-
normal cystic vascular channels lined by a single layer of endothe-
lial cells (ECs)with impaired tight junctions.2 Thesevessels are typi-
cally arranged in compact masses with no intervening brain
parenchyma, so the deriving vascular malformations are angio-
graphically occult. They may undergo acute intracranial hemor-
rhage (ICH), small subclinical bleeds, or slowdiapedesisof redblood
cells3 that produce a characteristic hemosiderin rim on magnetic
resonance imaging.4 In addition to causing stroke from ICH,5 CCM
can also provoke seizures,6 headaches, and focal neurological defi-
cits (FNDs).5 About 20% of cases are familial and characterized by
thepresenceofmultiple lesionsasopposed to sporadicCCM,which
hasnoprevalencewithin familiesand typicallypresentswithasingle
lesion. Radiation-induced cavernous malformation (RICM), a sub-
set of sporadic CCM, can occur in patients previously treated with
radiotherapy for brain tumors. Radiation-induced cavernous mal-
formations generally occur aftermany years, with the time of diag-
nosis inversely associated with age at radiation treatment. Radio-
graphically andhistologically, they are indistinguishable fromother
sporadic lesions and present similar rates of symptomatic hemor-
rhage.However,RICM isusuallydiagnosedatayoungerage, andpa-
tients are more likely to present with multiple lesions.7
Cerebral cavernous malformation has a genetic basis. Its mu-
tational landscapehasbeenfirst investigated in familial forms,where
predisposition to develop cavernomas is inherited through an au-
tosomal dominant pattern with incomplete penetrance. Linkage
studies allowed associating the occurrence of CCMs with loss-of-
function mutations in 1 of 3 genetic loci: CCM1 (KRIT1) at chromo-
some 7p,8 CCM2 (MGC4607) at 7q, and CCM3 (PDCD10) at 3q.9
IMPORTANCE Cerebral cavernous malformations (CCMs) are vascular lesions of the brain that
may lead to hemorrhage, seizures, and neurologic deficits. Most are linked to loss-of-function
mutations in 1 of 3 genes, namely CCM1 (originally called KRIT1), CCM2 (MGC4607), or CCM3
(PDCD10), that can either occur as sporadic events or are inherited in an autosomal dominant
pattern with incomplete penetrance. Familial forms originate from germline mutations, often
havemultiple intracranial lesions that grow in size and number over time, and cause an earlier
andmore severe presentation. Despite active preclinical research on a few pharmacologic
agents, clinical translation has been slow. Open surgery and, in some cases, stereotactic
radiosurgery remain the only effective treatments, but these options are limited by lesion
accessibility and are associated with nonnegligible rates of morbidity andmortality.
OBSERVATIONS We discuss the limits of CCMmanagement and introduce findings from in
vitro and in vivo studies that provide insight into CCM pathogenesis and indicate molecular
mechanisms as potential therapeutic targets. These studies report dysregulated cellular
pathways shared between CCM, cardiovascular diseases, and cancer. They also suggest the
potential effectiveness of proper drug repurposing in association with, or as an alternative to,
targeted interventions.
CONCLUSIONS AND RELEVANCE We proposemethods to exploit specific molecular pathways
to design patient-tailored therapeutic approaches in CCM, with the aim to alter its natural
progression. In this scenario, the lack of effective pharmacologic options remains a critical
barrier that poses an unfulfilled and urgent medical need.
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Corresponding mutation rates range between 53% and 65% for
CCM1, 15% and 19% for CCM2, and 10% and 16% for CCM3.10-12
Compared with those in CCM1 and CCM2, mutations in the CCM3
gene are associated with the most severe phenotype, defined as
an earlier onset of ICH and concomitance of multiple meningio-
mas in some cases.11 A 2-hit mechanism,13 whereby a germline
mutation in 1 allele of a CCM gene is later complemented by a
somatic mutation in the other allele, has been described as a trig-
ger in familial CCM.14 Although CCM is a worldwide disorder, a
specific mutation in the CCM1 gene is prevalent in northern
New Mexico. The origin of this founder mutation, also known as
the common Hispanic mutation–CCM1 , has been traced to a
Spanish ancestor who settled in New Mexico in the 1600s. The
common Hispanic mutation–CCM1 is responsible for a 15-fold
higher population prevalence and is present in virtually all cases
of familial CCM in the New Mexico Hispanic population.15 A
founder mutation in the CCM2 gene has been described in the
Ashkenazi Jewish population,16 while no founder mutations have
yet been found in the CCM3 gene. The association between geno-
type and phenotype in sporadic forms of CCM is less character-
ized, although the involvement of the same genes is emerging.
Mutations in either the CCM1, CCM2, or CCM3 gene have been
reported in 57% of sporadic cases with multiple lesions.12 Again, a
2-hit mechanism has been implicated, in which 2 spontaneous
somatic mutations occur sequentially at both alleles of 1 of the
known CCM genes.17 Yet other reports suggest a strong associa-
tion between the presence of cerebral lesions and polymor-
phisms in the CCM genes in sporadic cases.18 Whether similar
genetic alterations take place in RICM is not yet known. The
pathophysiology of RICM has been associated with vascular
injury19 and may lay along a spectrum of radiation-induced vascu-
lopathies that evolve from telangiectasia to CCM.
Clinical Presentation, Natural History,
and Current Management of CCM
About 60% of CCM lesions present as clinically silent1 and are dis-
covered incidentally on brain magnetic resonance imaging ob-
tained for other reasons. Sporadic CCM lesions may be associated
with a developmental venous anomaly,20while familial forms typi-
cally present with multiple lesions (even hundreds). In familial pa-
tients, modern diagnostic techniques, such as susceptibility-
weighted imaging, detect more lesions than were previously
identifiedwithT2-weightedgradientechosequences.21 These tech-
niques also showthatnewvascular lesions constantly formdenovo
with age.22
In symptomatic cases, the most common presentation is sei-
zures, followed by ICH and FND in the absence of an acute
hemorrhage.5 The 5-year risk of first-time seizure in asymptomatic
CCM is 4% but increases to 6% in patients presenting with ICH or
FND.23 Reported rates of ICHvarywidely in the literature. In 2008,
theAngiomaAllianceScientificAdvisoryBoardstandardizedthedefi-
nition of CCM-associated ICH.5 A meta-analysis24 across 7 patient
cohorts using this newdefinition reportedanoverall 5-year ICH risk
of 15.8%.24 Comparedwith supratentorial and cerebellar CCMs, le-
sions located in the brainstem carry the worst prognosis and high-
est neurologic morbidity, with the combined risk of ICH and FND
escalating to more than 50% at 5 years.24,25 Moreover, the annual
riskof ICHin incidentallydiscoveredorpreviouslyasymptomaticCCM
issignificantlyhigher in familial (4.3%to6.5%)26comparedwithspo-
radic cases (0.08% to 0.1%).1
The clinical approach to CCM depends on presentation, lesion
location, and symptom severity (Figure 1). In 2017, the Angioma
Alliance Scientific Advisory Board published expert guidelines for
clinical management of CCM,27 and we refer the reader to this
publication. Briefly, a 3-generation family history should be col-
lected at the time of diagnosis. Genetic testing, including
mutation/deletion analysis of CCM1, CCM2, and CCM3 genes, is
recommended in all cases with multiple lesions without a history
of radiation exposure or a positive family history. Further genetic
counseling should be offered when a mutation is discovered in the
proband. Asymptomatic lesions should be managed conserva-
tively with imaging, although routine imaging follow-up is recom-
mended only in the presence of new or worsening symptoms.27
Cerebral cavernous malformation–related epilepsy is initially
treated with antiepileptic drugs until it becomes refractory. Sur-
gery may be offered for medically intractable epilepsy, supported
by evidence for early surgical resection of single lesions to obtain
durable seizure control.6 In general, surgery is reserved for symp-
tomatic lesions owing to its intrinsic risk. Postsurgical morbidity
and mortality increase after lesion removal from certain locations;
those in eloquent/deep areas and brainstem have the highest risk.
Because the overall 5-year probability of a second ICH is as high as
29.5%, surgery is recommended after a first symptomatic bleed
for lesions in favorable locations.28 Advances in surgical naviga-
tion, tractography,29 and awake mapping30 permit safe resection
of lesions in eloquent locations including the brainstem.31 In con-
trast, surgery is often delayed in the case of deep lesions until the
appearance of a second symptomatic bleed. Stereotactic radiosur-
gery (SRS) is an alternative option for single lesions in surgically
inaccessible areas or in locations with high surgical morbidity,
although it is not recommended for asymptomatic lesions or in
familial cases.32
Figure 1. Flowchart Summarizing the Clinical Course of Cerebral
CavernousMalformation (CCM) andMedical/Surgical Guidelines
CCM presentation
(increasing severity)
Treatment
(current guidelines)
Asymptomatic (incidental) Conservative
Symptomatic: first-time seizure Antiepileptics
Symptomatic: refractory epilepsy Surgery
Symptomatic: first ICH (supratentorial) Surgery
Symptomatic: first ICH (brainstem, deep nuclei) Conservative
Symptomatic: second ICH (brainstem, deep nuclei) Surgery/radiation
Depending on the clinical presentation, different strategies are recommended
for CCM. For asymptomatic/incidentally discovered lesions, conservative
management is the elected choice. Surgery is considered for easily
accessible lesions to mitigate the pathological burden. The only medical
treatment included in standardmanagement is pharmacologic control of
seizures when the condition is not refractory to antiepileptic drugs. However,
in this case, evidence suggests early surgery for better seizure control. In all
other cases of symptomatic CCM, surgery is the only accepted approach.
There is limited evidence for the application of radiation therapy, which is
reserved for surgically inaccessible lesions. ICH indicates intracranial
hemorrhage.
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Failure of Current Strategies
AlmostallpatientswithCCM-relatedseizuresdevelopepilepsywithin
5 years from diagnosis,23 and up to 40% become refractory to an-
tiepileptic medications,33 the only pharmacologic treatment cur-
rently indicated for CCM.While surgical resection of a single symp-
tomatic lesion results in good seizure control, a favorable outcome
is dependent on the duration of seizures. Seizure control after sur-
gery is poor if thedurationof epilepsyhasbeenmore than2years34
because frequent asymptomatic microbleeds may induce epilep-
togenic gliosis in a perilesional brain.35 For all other symptoms, the
mainstay treatment options are surgical resection of the lesion and
SRS in selected cases, although they aremarred by inherent limita-
tions. For example, surgery is often too dangerous or not possible
for deep-seated lesions in locations such as the thalamus and
brainstem. Moreover, much of the experience on surgical man-
agement of CCM comes from highly-specialized centers, which
limits generalization to a community setting. Even in experienced
hands, the overall risk of major surgical morbidity, such as nonfa-
tal stroke, is around 6%.28 For deep-seated lesions, such as those
in the basal ganglia and thalamus, this risk approaches 18%, with
an operative mortality of 2%.36 For brainstem lesions, surgical
resection results in significant postoperative morbidity in 45% of
the cases. Of these, up to 12% of patients require tracheostomy
and feeding tubes, although they tend to improve over time.37
Likewise, SRS, when applicable, has a roughly 2-year latency
period before the annual risk of hemorrhage is significantly
reduced and is limited to small lesions with treatment volumes
less than 2 to 3 cm3 to limit marginal doses.38 Furthermore, there
is still some debate as to whether the observed effects of SRS are
indicative of efficacy or a mere reflection of the natural evolution
of the disease.27
Even in familial cases, for which our understanding of disease
progression is more comprehensive, incomplete penetrance and
variable presentation within families preclude a reliable risk
estimation,39 hence the necessity for continuous follow-up and/or
prompt surgical intervention at the appearance or worsening of
symptoms.Nevertheless,ourgrowingknowledgeonthenaturalpro-
gression of CCM suggests that there could be a window of oppor-
tunity to affect the disease course from time of diagnosis to devel-
opment of aggressive behavior. In sporadic cases, exploiting this
windowwouldcontrol lesiongrowthandmicrohemorrhages to limit
or abrogate symptomatic ICHandepileptogenesis,whichcannotbe
achieved with current treatment options. Similarly, there is no ef-
fectiveapproach todelay lesiongrowthanddenovo formation typi-
cal of familial cases, which constantly produce new vascular
malformations22 at a rate that can reach 2.7 per patient per year in
the presence of mutations in the CCM3 gene.40
Altered Cellular andMolecular Processes
Underlying CCM Lesion Formation
Studies have made progress to link basic and translational science
totheemergenceofCCMlesions,whichrevealsnovel,putativetreat-
ment targets.While a comprehensiveoverviewofCCM-related cel-
lularmechanismsandsignalingpathwaysgoesbeyond the scopeof
this review, here we summarize the core events that are critical to
elucidate disease pathology and design effective next-generation
therapies.
Cerebral cavernousmalformationsare formedbyactivated, an-
giogenic ECs41 that induce local inflammation and oxidative stress
owing to impaired autophagy.42 At the cellular level, these ECs un-
dergo endothelial-to-mesenchymal transition (EndMT), a process
common to other vascular anomalies, such as atherosclerosis and
hereditaryhemorrhagic telangiectasia,43andsimilar to theepithelial-
to-mesenchymal transition (EMT) observed in cancer cells. Several
studiesconfirmedthatEndMT44,45underliesCCMformation inboth
familial46,47 and sporadic48 cases. Endothelial cells subjected to
this transition acquire a stem cell–like and mesenchymal cell–like
phenotype characterized by loss of proper polarization, increased
migration, and decreased cell-cell and cell-matrix adhesion. Con-
sequences of EndMT are abnormal architecture and leakiness of
brain blood vessels, and loss of contact between ECs and nervous
cells, which ultimately lead to formation of the typical mulberry-
shaped cavernae in the context of an angiogenic and inflamma-
tory microenvironment.
The molecular mechanisms underlying these biologic and
cellular processes have been first studied in iCCM1, an inducible,
EC-specific CCM1 knockout transgenic mouse that reproduces the
phenotype observed in patientswith loss-of-functionmutations in
the CCM1 gene, namely, lesions within the central nervous system
thatarecomposedofdilatedmultilumenvascularchannelswithsigns
of vascular leakage.49BrainECsderived from iCCM1mice show loss
of cell polarity and disruption of cell-cell contacts owing to altered
vascular endothelial (VE)–cadherin distribution along with Notch
inhibition,49 which may induce angiogenesis by releasing a nega-
tivecontrolonextracellular-signal-regulatedkinase50andephrin re-
ceptorB4.51 Thesecells showhyperactivatedEndMTsignalingpath-
ways: theyoverexpressbonemorphogeneticprotein6,which leads
tohyperactivationoftransforminggrowthfactorβreceptorwithcon-
sequent overexpression of β-catenin, increased small mothers
against decapentaplegic phosphorylation, and translocation to the
nucleus, followed by upregulation of stem cell, inflammatory, and
mesenchymal genes including Kruppel-like factor 4 (Klf4)49
(Figure2). Thekey roleofKLF transcription factors inCCMhasbeen
corroborated in an independentmousemodel of EC-specific CCM1
gene loss, inwhichupregulationofKlf2 andKlf4genesoccurs in the
earlyphasesof lesionformation,52and inmicedefective for theCCM2
gene.53 Likewise, increasedKLF2andFLF4protein levelshavebeen
observed in both familial and sporadic CCM lesions and are consid-
ered a hallmark of CCM-related EndMT (Table 1).47-49,52-54
Inaddition to theseobservations inCCM1andCCM2models, the
peculiarphenotypeassociatedwithCCM3genemutationshasbeen
specificallyexamined inmicewith inducibleEC-specific lossofCCM3.
In these mice, a distinctive tract is an increased exocytosis and se-
cretion of the proangiogenic factor angiopoietin-254 (Figure 2),
coupledwith decreasedEC adhesion andpericyte coverage,which
causes disorganized blood vessels with enlarged lumen in the cer-
ebellar and retinal venous plexuses. A similar pattern of vessel dis-
organization associated with high levels of angiopoietin-2 has also
been observed in surgical specimens and lesion-derived ECs from
patients with CCM3 genemutations54 (Table 1).
Thequestion remains as tohowthesemolecular pathways and
cellular processes derive from the genetic defects identified in
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patientswith CCM.Quite simply, a loss-of-functionmutation in 1 of
theCCMgenescausesdefectiveproductionof thehomonymouspro-
tein. So, the lack of either the CCM1, CCM2, or CCM3 protein is the
molecular trigger thatultimately facilitatesdiseaseonset.The3CCM
Figure 2. Schematic Representation of Cerebral CavernousMalformation (CCM) Onset and Proposed Therapeutic Interventions
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In normal brain endothelial cells (ECs), the 3 CCM proteins form complete CCM
and striatin-interacting phosphatase and kinase (STRIPAK) complexes. Under
these conditions, cells are properly polarized and tightly connected to each
other by vascular endothelial (VE)–cadherin and to the extracellular matrix by β1
integrin, so cell adhesion prevails over migration. Blood vessels show a properly
organized lumenwith a continuous endothelial layer. Angiogenesis is inhibited
through activation of a Notch-mediated negative circuit, exocytosis is restricted
by inhibition of Cdc42, and oxidative stress is controlled. Loss of either the
CCM1, CCM2, or CCM3 protein disrupts these complexes. The consequent loss
of VE-cadherin organization is paralleled by hyperactivation of
mitogen-activated protein kinase kinase kinase 3 (MEKK3), RhoA/Rho-
associated protein kinase (ROCK) and Cdc42, overexpression of Kruppel-like
factor 2 (KLF2) and KLF4with induction of transforming growth factor β (TGFβ)
signaling, and inhibition of Notch. Brain ECs undergoing endothelial-to-
mesenchymal transition (EndMT) lose their physiological adhesion and
polarization properties and acquire a migratory phenotype, thus disrupting the
endothelial barrier. Increased oxidative stress, exocytosis, inflammation and
angiogenesis, and decreased autophagy emerge as pathogenic events during
CCM lesion formation (in red). Based on these biological premises, preclinical
studies and ongoing clinical trials advise the repurposing of several targeted
drugs for CCM treatment (in green). ANGPT2 indicates angiopoietin-2; BMP,
bonemorphogenetic protein; DMH1, dorsomorphin homolog 1; EphB4, ephrin
receptor B4; ICAP1, integrin cytoplasmic associated protein-1; MST, mammalian
sterile 20-like kinase 3; mTor, mammalian target of rapamycin; SMAD, small
mothers against decapentaplegic; TLR-4, toll-like receptor 4.
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proteins do not possess intrinsic enzyme activity and are therefore
considered as scaffolds or adaptors.55Whenpresent at normal lev-
els, theybind toeachother in theso-calledCCMcomplex,whichalso
includes VE-cadherin,56 integrin cytoplasmic associated
protein-1,57,58sortingnexin 17,59andRap160asdirect interactorswith
CCM1 and mitogen-activated protein kinase kinase kinase 3
(MEKK3)61 andSmurf162 asdirect interactorswithCCM2.On lossof
either theCCM1, CCM2, orCCM3protein anddisruptionof theCCM
complex, these interactors areno longer regulated. Therefore, they
can induce disaggregation of adherens junctions (VE-cadherin),56
dysregulation of β1 integrin functions (integrin cytoplasmic associ-
atedprotein-1 andsortingnexin 17),57-59overexpressionofKLF2and
KLF4 (MEKK3),52 and hyperactivation of RhoA signaling via Rho-
associatedproteinkinase (ROCK) (Rap1, Smurf1, andMEKK3)53,60,62
(Figure 2). Collectively, these altered pathways result in loss of cell
polarity and decreased cell adhesion associated with disruption of
endothelial barrier integrity andabnormal vascular lumen, all events
associatedwith theonsetofEndMT(Table2).52,53,57,59-68While the
presenceof CCM1 andCCM2proteins is restricted to theCCMcom-
plex, theCCM3protein is also found in the striatin-interactingphos-
phatase and kinase (STRIPAK) complex, where it binds to germinal
center kinase III members: mammalian sterile 20-like kinase 3 also
known as serine/threonine kinase 24 (STK24),69 suppressor of ki-
nase 1 (STK25),67 andmammalian sterile 20-like kinase4(STK26)66
(Figure 2). Loss of the CCM3 protein and consequent disruption
of the STRIPAK complex leads to hyperactivation of Cdc4269
accompanied by induction of cell migration,67 alteration of cell
polarity,66 impairedability to containoxidative stress,68 andabnor-
mal exocytosis62-64 (Table 2), which explains the increased secre-
tionofangiopoietin-2observed invivo.54Althoughmorestudiesare
needed to dissect the consequences of CCM3 loss-of-functionmu-
tations, it seems reasonable that thesegeneticdefectswould cause
Table 2. Interactors of the CCMProteins Identified by In Vitro Studies, Their Physiological Functions,
and Pathogenic EventsMediated by These Interactors Following Disruption of Either the CCM
or STRIPAK Complexes
Complex
CCM
Protein Direct Interactor
Physiological Role
of the Interactor
Pathological Role of the
Interactor in CCM Source
CCM CCM1 VE-cadherin Main constituent of
adherens junctions
Disrupted cell-cell
contacts, loss of cell
polarity and impaired
lumen organization
Lampugnani et al56
CCM CCM1 Rap1 Regulation of
RhoA/ROCK
Hyperactivated
RhoA/ROCK: decreased
cell adhesion, disruption
of endothelial barrier
Serebriiskii et al60
CCM CCM1 ICAP1
and SNX17
Regulation of β1
integrin
Dysregulated β1 integrin:
decreased cell adhesion
Zhang et al57
Czubayko et al59
CCM CCM2 MEKK3 Several functions in
vascular
development
among which
regulation of
RhoA/ROCK
Hyperactivated
RhoA/ROCK, vascular
leakage due to disruption
of endothelial barrier,
overexpressed KLF2/4
Zhou et al52
Whitehead et al53
Fisher et al61
CCM CCM2 Smurf1 Degradation of
RhoA
Hyperactivated
RhoA/ROCK: decreased
cell adhesion
Crose et al.62
STRIPAK CCM3 MST3/STK24 Regulation of
Cdc42
Hyperactivated Cdc42:
increased exocytosis
Lant et al63
Song et al64
Zhang et al65
STRIPAK CCM3 SOK1/STK25
MST4/STK26
Preservation of
Golgi integrity and
centrosome
orientation,
protection from
oxidative stress
Increased migration, loss
of cell polarity, oxidative
stress
Ma et al66
Fidalgo et al67,68
Abbreviations: CCM, cerebral
cavernous malformation;
ICAP1, integrin cytoplasmic
associated protein-1;
KLF, Kruppel-like factor;
MEKK3, mitogen-activated protein
kinase kinase kinase 3;
MST3, mammalian sterile 20-like
kinase 3; ROCK, Rho-associated
protein kinase; SNX17, sorting nexin
17; STK, serine/threonine kinase;
SOK, suppressor of kinase;
STRIPAK, striatin-interacting
phosphatase and kinase;
TGFβ, transforming growth factor β;
VE, vascular endothelial.
Table 1. Dysregulated Signaling Pathways and Cellular Processes Identified In Vivo in CCMAnimal Models
and Ex Vivo in Patient-Derived Specimens (Surgical Samples and/or Lesion-Derived ECs)
Mutated Gene Study Model Affected Signaling Pathways and Cellular Processes Source
Ccm1 Transgenic mice Disrupted VE-cadherin junctions; activated TGFβ
signaling; upregulated Klf4 among other mesenchymal,
stem cell, and inflammatory genes; inhibited Notch
Maddaluno et al49
Ccm1 Transgenic mice Upregulated Klf2 and Klf4 genes Zhou et al52
Ccm2 Transgenic mice Upregulated Klf2 and Klf4 genes Whitehead et al53
CCM1, CCM3
Familial and
sporadic
Patient-derived
specimens
Overexpressed KLF2 and KLF4 proteins Zhou et al52
CCM1, CCM2,
CCM3 Familial
and sporadic
Patient-derived
specimens
Disrupted VE-cadherin junctions; activated TGFβ
signaling; overexpressed KFL4 among other
mesenchymal, stem cell, and inflammatory protein
markers
Bravi et al48
Cuttano et al47
Ccm3 Transgenic mice Increased secretion of ANGPT2 Jenny Zhou et al54
CCM3 Patient-derived
specimens
Increased levels of ANGPT2
Abbreviations: ANGPT2,
angiopoietin-2; CCM, cerebral
cavernous malformation;
EC, endothelial cell; KLF, Kruppel-like
factor; TGFβ, transforming growth
factor β; VE, vascular endothelial.
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additive effects because the CCM3 protein contributes to both the
CCM and STRIPAK complexes. This would explain the extremely
severe phenotype observed in patients with loss-of-function
mutations of the CCM3 gene.11
New Target Inhibitors and Drug Repurposing
Undergoing Preclinical or Clinical Investigation
The biological and molecular bases of CCM suggest that specifi-
cally dysregulatedpathwayswill yield therapeutic targets (summa-
rized inTable3).46,49-51,53,70-76Fromabroaderperspective, theCCM
proteins regulate biological processes whose dysregulation is also
observed in cardiovascular diseases and cancer, namely decreased
autophagy70paralleledby increasedangiogenesis,77 inflammation,42
and oxidative stress.78 The prevalence of these processes implies
that specific inhibitors could be effective in the symptomatic treat-
ment of CCM. This hypothesis is confirmed by preclinical studies in
whichdefectiveautophagywaspartially restoredbypharmacologi-
cal inhibition ofmammalian target of rapamycin.70 In addition, the
hyperactivation of ERK50 and EphB4 kinase51 observed in CCM-
related angiogenesis was reversed by treatment with the small-
molecule inhibitors sorafenib50 and NVP-BHG712 (NVP),51 respec-
tively.At thecellular level,EndMTactsasadrivingmechanisminCCM
lesion onset both in animalmodels andpatients.46-49 Consistently,
pharmacologic inhibition of transforming growth factor β signaling
withdorsomorphinhomolog 1 (targetingbonemorphogenetic pro-
tein), LY364947, SB431542 (targeting small mothers against
decapentaplegic),49 or sulindac (targeting β-catenin)46 proved ef-
fective in revertingtheCCMphenotype.TheMEKK3-KLF2/4axiswas
also successfully targeted with inhibitors of the innate immune re-
ceptor toll-like receptor 4, which was incidentally identified as up-
stream inducer of this signaling pathway inmousemodels of gram-
negative gut infections.71 RhoA,whose hyperactivation in CCMhas
been reported in several in vitro and in vivo studies, is another suc-
cessful target with the kinase inhibitor fasudil72,79 and the indirect
inhibitor simvastatin,53whichnormalizedvascularpermeability and
decreased lesion number in transgenic mice. Some of the previ-
ouslymentioneddrugs are alreadyon themarket for other applica-
tions and could be repurposed with relative ease, namely the
mTor inhibitors, sirolimusandeverolimus, and themultikinase inhibi-
tor, sorafenib, approved for cancer treatment; sulindac, a nonsteroi-
dalantiinflammatorydrug; toll-likereceptor4 inhibitors,originallyde-
velopedforsepsistreatment;fasudil,avasodilatorusedtotreatcerebral
vasospasm; and simvastatin, a lipid-loweringmedication. In addition
totheserationallydesignedapproaches,othercandidates fordrugre-
purposing have emerged from screening studies that assessedmar-
keteddrugs in the contextofCCM.For example, cholecalciferol (vita-
Table 3. Proposed Drug Repurposing and Targeted Approaches
Study Type and Drug Targets in CCM Approved Application Source
In vitro and in vivo
Rapamycin analogues mTor Antineoplastic drugs Marchi et al70
Sorafenib ERK Antiangiogenic drug Wüstehube et
al50
NVP EphB4 None You et al51
DMH1 TGFβ signaling: BMP None Maddaluno et
al49
LY364947
SB431542
TGFβ signaling: SMAD None Maddaluno et
al49
Sulindac TGFβ signaling: β-catenin Nonsteroidal antiinflammatory drug Bravi et al46
TLR4-blocking agents MEKK3-KLF2/4
down-stream of TLR4
signaling
Treatment of sepsis Tang et al71
Fasudil RhoA Vasodilator, treatment of cerebral
vasospasm
McDonald et al72
Simvastatin RhoA Statin, treatment of
hypercholesterolemia
Whitehead et al53
Drug-screening platforms
Vitamin D3 Potential effect on
oxidative stress and/or
inflammation
Vitamin supplement Gibson et al73
Tempol Potential effect on
oxidative stress and/or
inflammation
Antioxidant and anti-inflammatory
drug
Gibson et al73
Bosutinib, saracatenib,
danusertib, sunitinib,
and desatinib
MST3/STK24 Antineoplastic drugs Olesen et al74
Incidental findings and
case reports
Bevacizumab VEGFA Antiangiogenic drug Aguilera et al75
Propranolol Potential effect on
angiogenesis
β-Adrenergic blocker, treatment of
hypertension, and infantile
hemangioma
Zabramski et al76
Clinical trials
Simvastatin RhoA Statins, treatment of
hypercholesterolemia
Not yet published
Atorvastatin RhoA Statins, treatment of
hypercholesterolemia
Not yet published
Abbreviations: CCM, cerebral
cavernous malformation;
DMH1, dorsomorphin homolog 1;
EphB4, ephrin receptor B4;
ERK, extracellular-signal-regulated
kinase; KLF, Kruppel-like factor;
MEKK3, mitogen-activated protein
kinase kinase kinase 3;
MST3, mammalian sterile 20-like
kinase 3; mTor, mammalian target of
rapamycin; STK, serine/threonine
kinase; TGFβ, transforming growth
factor β; TLR4, toll-like receptor 4;
VEGFA, vascular endothelial growth
factor A.
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min D3) and tempol (a free-radical scavenger) emerged from a
combined in vitro–in vivo screening of 2100molecules as efficient in
reducing lesion burden in Ccm2 transgenic mice.73 Based on their
known pharmacologic action, these compoundswould be expected
to control CCMprogression by inhibiting inflammation and oxidative
stress. In another study, 14of277 testedcompoundswereconfirmed
as inhibitorsofMST3/STK24kinaseactivity,5ofwhicharealreadyap-
provedby theUSFoodandDrugAdministrationor inphase II/III clini-
cal trials for cancer treatment (namely, bosutinib, saracatenib, danu-
sertib, sunitinib, and desatinib).74
Whileseveralcompoundsarebeinginvestigatedinpreclinicalstud-
ies,onlyafewpharmacologicagentshavereachedclinical testing.The
potential efficacy of targeting angiogenesis in CCM is supported by 2
case reports: theobservationof incidental resolution inacaseofCCM
on treatmentwith the anti–vascular endothelial growth factorAanti-
body, bevacizumab,75 and lesion regression and reduction of symp-
tomatic ICH in 2patientswith CCMon treatmentwith propranolol,76
a β-adrenergic blocker and an antiangiogenic agent used to treat hy-
pertension and infantile hemangioma.80 Despite these encouraging
observations, toour knowledge, there arenoongoing clinical trials to
evaluate antiangiogenic drugs in CCM. The focus remains on repur-
posingstatins inanattempttorestorephysiologicvascularpermeabil-
ity in brain capillaries. Statins are approved for the treatment of
hypercholesterolemia because they are powerful inhibitors of 3-hy-
droxy-3-methyl-glutarylcoenzymeAreductase,therate-controllingen-
zyme incholesterol synthesis.However, theyalso impair posttransla-
tionalmodificationof small GTPaseproteins, such asRhoA, andhave
provenefficient in revertingtheCCMphenotype intransgenicmice.53
A first, randomizedearlyphase I trial (NCT01764451) is an imaging in-
vestigation conductedby our group inNewMexico to study vascular
permeability across the blood-brain barrier with dynamic contrast-
enhanced magnetic resonance imaging. The primary outcome will
evaluatewhethersimvastatin improves theblood-brainbarrier integ-
rity in patientswith familial CCM1. The secondaryoutcomewill corre-
late permeability data with new lesion formation or growth. A sec-
ond,phase I/II randomizedclinical trial (NCT02603328) isplannedto
evaluate the long-term effect of atorvastatin on lesion growth in pa-
tientswithsymptomatic(hemorrhagic)CCM.Theresultsofthesetrials
are not yet available.
Conclusions
Despite being a rare disease, CCM is highly prevalent in certain re-
gions, such as New Mexico, and a substantial percentage of pa-
tientsexperienceseveresymptoms.Whileclinically silent lesionsare
left untreated,patientswith symptoms, suchas seizure, ICH, and/or
FND,canconsidersurgicaltreatmentoptions,butonlyinspecificcases.
Besides antiepileptic drugs, towhich up to40%of patients become
refractory,nopharmacologicmanagementofCCMhasproveneffec-
tiveenoughtobetranslatedtotheclinic (Figure 1).Astrategythatad-
dresses lesion growth, number, and inherent hemorrhagic potential
is needed to alter the disease trajectory in both asymptomatic and
symptomaticcases. Indeed, interferingwiththenaturaldiseasecourse
inCCMwoulddrastically reduce risky surgeries, aswell as provide an
option to otherwise incurable patients.
We propose to exploit the growing knowledge on themolecu-
lar biology that underlies CCM to design patient-tailored therapeu-
tics (Figure 2). Cerebral cavernousmalformation proteins interact,
either directly or indirectly, with several cellular partners. Cerebral
cavernousmalformation 1, CCM2, andCCM3are componentsof the
CCM complex, while CCM3 is peculiarly included into the STRIPAK
complex.LossofCCMproteins isassociatedwithadisruptionofsuch
complexes and activates signaling pathways in brain ECs, eventu-
ally leading to lesion formation (Table 1 and Table 2). Blocking
these dysregulated pathways with targeted inhibitors has proven
therapeutic efficacy in animal models and require further investi-
gation. Moreover, several pathologic features of CCM overlap
with those observed in cardiovascular diseases and cancer,
namely autophagy, angiogenesis, inflammation, and oxidative
stress. These commonalities support the feasibility of drug repur-
posing. In this perspective, 2 pioneering and ongoing clinical trials
are evaluating the efficacy of statins to control CCM progression
(Table 3).
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